Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial

Research output: Contribution to journalJournal articlepeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Maksymowych, Walter P ; Østergaard, Mikkel ; Landewé, Robert ; Barchuk, William ; Liu, Ke ; Gilles, Leen ; Hendrikx, Thijs ; Besuyen, Robin ; Baraliakos, Xenofon. / Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis : results from the TORTUGA trial. In: Rheumatology (Oxford, England). 2022 ; Vol. 61, No. 6. pp. 2388-2397.

Bibtex

@article{e483d8c15a654afab89368c5f3c08180,
title = "Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial",
abstract = "OBJECTIVES: To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial.METHODS: In the TORTUGA trial, patients with AS received filgotinib 200 mg (n = 58) or placebo (n = 58) once daily for 12 weeks. In this post hoc analysis, spine MRIs were evaluated using the Canada-Denmark (CANDEN) MRI scoring system to assess changes from baseline to week 12 in total spine and subscores for inflammation, fat, erosion and new bone formation (NBF) at various anatomical locations. Correlations were assessed between CANDEN inflammation and clinical outcomes and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI scores and between baseline CANDEN NBF and baseline BASFI and BASMI scores.RESULTS: MRIs from 47 filgotinib- and 41 placebo-treated patients were evaluated. There were significantly larger reductions with filgotinib vs placebo in total spine inflammation score and most inflammation subscores, including posterolateral elements (costovertebral joints, transverse/spinous processes, soft tissues), facet joints and vertebral bodies. No significant differences were observed for corner or non-corner vertebral body inflammation subscores, spine fat lesion, bone erosion or NBF scores. In the filgotinib group, the change from baseline in the total inflammation score correlated positively with the SPARCC spine score. Baseline NBF scores correlated with baseline BASMI but not BASFI scores.CONCLUSIONS: Compared with placebo, filgotinib treatment was associated with significant reductions in MRI measures of spinal inflammation, including in vertebral bodies, facet joints and posterolateral elements.TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT03117270.",
keywords = "Humans, Inflammation/diagnostic imaging, Magnetic Resonance Imaging/methods, Pyridines, Severity of Illness Index, Spine/diagnostic imaging, Spondylarthritis/pathology, Spondylitis, Ankylosing/diagnostic imaging, Triazoles, Vertebral Body, Zygapophyseal Joint, therapeutics, MRI, AS, filgotinib, inflammation",
author = "Maksymowych, {Walter P} and Mikkel {\O}stergaard and Robert Landew{\'e} and William Barchuk and Ke Liu and Leen Gilles and Thijs Hendrikx and Robin Besuyen and Xenofon Baraliakos",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.",
year = "2022",
month = may,
day = "30",
doi = "10.1093/rheumatology/keab758",
language = "English",
volume = "61",
pages = "2388--2397",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "6",

}

RIS

TY - JOUR

T1 - Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis

T2 - results from the TORTUGA trial

AU - Maksymowych, Walter P

AU - Østergaard, Mikkel

AU - Landewé, Robert

AU - Barchuk, William

AU - Liu, Ke

AU - Gilles, Leen

AU - Hendrikx, Thijs

AU - Besuyen, Robin

AU - Baraliakos, Xenofon

N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

PY - 2022/5/30

Y1 - 2022/5/30

N2 - OBJECTIVES: To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial.METHODS: In the TORTUGA trial, patients with AS received filgotinib 200 mg (n = 58) or placebo (n = 58) once daily for 12 weeks. In this post hoc analysis, spine MRIs were evaluated using the Canada-Denmark (CANDEN) MRI scoring system to assess changes from baseline to week 12 in total spine and subscores for inflammation, fat, erosion and new bone formation (NBF) at various anatomical locations. Correlations were assessed between CANDEN inflammation and clinical outcomes and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI scores and between baseline CANDEN NBF and baseline BASFI and BASMI scores.RESULTS: MRIs from 47 filgotinib- and 41 placebo-treated patients were evaluated. There were significantly larger reductions with filgotinib vs placebo in total spine inflammation score and most inflammation subscores, including posterolateral elements (costovertebral joints, transverse/spinous processes, soft tissues), facet joints and vertebral bodies. No significant differences were observed for corner or non-corner vertebral body inflammation subscores, spine fat lesion, bone erosion or NBF scores. In the filgotinib group, the change from baseline in the total inflammation score correlated positively with the SPARCC spine score. Baseline NBF scores correlated with baseline BASMI but not BASFI scores.CONCLUSIONS: Compared with placebo, filgotinib treatment was associated with significant reductions in MRI measures of spinal inflammation, including in vertebral bodies, facet joints and posterolateral elements.TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT03117270.

AB - OBJECTIVES: To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial.METHODS: In the TORTUGA trial, patients with AS received filgotinib 200 mg (n = 58) or placebo (n = 58) once daily for 12 weeks. In this post hoc analysis, spine MRIs were evaluated using the Canada-Denmark (CANDEN) MRI scoring system to assess changes from baseline to week 12 in total spine and subscores for inflammation, fat, erosion and new bone formation (NBF) at various anatomical locations. Correlations were assessed between CANDEN inflammation and clinical outcomes and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI scores and between baseline CANDEN NBF and baseline BASFI and BASMI scores.RESULTS: MRIs from 47 filgotinib- and 41 placebo-treated patients were evaluated. There were significantly larger reductions with filgotinib vs placebo in total spine inflammation score and most inflammation subscores, including posterolateral elements (costovertebral joints, transverse/spinous processes, soft tissues), facet joints and vertebral bodies. No significant differences were observed for corner or non-corner vertebral body inflammation subscores, spine fat lesion, bone erosion or NBF scores. In the filgotinib group, the change from baseline in the total inflammation score correlated positively with the SPARCC spine score. Baseline NBF scores correlated with baseline BASMI but not BASFI scores.CONCLUSIONS: Compared with placebo, filgotinib treatment was associated with significant reductions in MRI measures of spinal inflammation, including in vertebral bodies, facet joints and posterolateral elements.TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT03117270.

KW - Humans

KW - Inflammation/diagnostic imaging

KW - Magnetic Resonance Imaging/methods

KW - Pyridines

KW - Severity of Illness Index

KW - Spine/diagnostic imaging

KW - Spondylarthritis/pathology

KW - Spondylitis, Ankylosing/diagnostic imaging

KW - Triazoles

KW - Vertebral Body

KW - Zygapophyseal Joint

KW - therapeutics

KW - MRI

KW - AS

KW - filgotinib

KW - inflammation

UR - http://www.scopus.com/inward/record.url?scp=85131225650&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keab758

DO - 10.1093/rheumatology/keab758

M3 - Journal article

C2 - 34647992

VL - 61

SP - 2388

EP - 2397

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 6

ER -

ID: 70405349